Overcoming leukemia heterogeneity by combining T cell engaging bispecific antibodies
Background Leukemia represents about 5% of all human cancers. Despite advances in therapeutics, a substantial number of patients succumb to the disease. Several subtypes of leukemia are inherently more resistant to treatment despite intensive chemotherapy or targeted therapy.Methods Here we describe...
محفوظ في:
| المؤلفون الرئيسيون: | , , , |
|---|---|
| التنسيق: | Artigo |
| اللغة: | Inglês |
| منشور في: |
BMJ Publishing Group
2020-10-01
|
| سلاسل: | Journal for ImmunoTherapy of Cancer |
| الوصول للمادة أونلاين: | https://jitc.bmj.com/content/8/2/e001626.full |
| الوسوم: |
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!
|